Immix Biopharma (IMMX) Stock: Buy, Sell, or Hold?
IMMX - Immix Biopharma, Inc. Common Stock
$9.68
-0.55 (-5.38%)
▼
5d:
-11.76%
30d:
-30.66%
90d:
-7.37%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 06, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 22, 2026 at $12.35 · last confirmed Sep 29, 2026
Strength: 6.7/10
Get Alerted When IMMX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IMMX is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IMMX is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IMMX is currently trading at $9.68, which is considered oversold relative to its 30-day fair value range of $11.24 to $13.88.
Technical Outlook: Technically, IMMX is in a strong uptrend. The price is currently testing key support at $9.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: IMMX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $24.30 (+151.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMMX is in a strong uptrend. The price is currently testing key support at $9.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: IMMX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $24.30 (+151.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.24 -
$13.88
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 151.0% below Wall St target ($24.30)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.24 -
$13.88
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.48
Resistance Level
$12.90
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.42
Wall Street Target
$24.30
(+151.0%)
Share & Embed Analysis
Last updated: October 04, 2026 10:20 AM ET
Data refreshes hourly during market hours. Next update: 11:20 AM
Data refreshes hourly during market hours. Next update: 11:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMMX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
23 analysts |
$139 | 55 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
16 analysts |
$141 | 63 BUY |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
17 analysts |
$120 | 56 HOLD |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
13 analysts |
$74 | 66 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 40 SELL |
